Main News

10/17/2019

IVI and the USask’s VIDO-InterVac Exchange MOU to Advance Vaccine Research

Professor Peter Stoicheff, President of USask (left), and Dr. Jerome Kim, DG of IVI, sign an MOU at IVI’s headquarters   October 16, 2019, SEOUL, Korea — IVI and the University of Saskatchewan’s (USask) VIDO-InterVac, a global leader in infectious disease research and vaccine development, […]
10/29/2019

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

October 28, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI) has received a $4.5 million grant from the Bill & Melinda Gates Foundation to simplify the current oral cholera vaccine (OCV) and further increase its accessibility. To date, the Gates Foundation has […]
11/04/2019

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

Institute expected to increase contributions to vaccine development activities worldwide   November 1, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI), an international organization for vaccine development and delivery headquartered in Seoul, has been granted Good Clinical Laboratory Practice (GCLP) certification by […]
11/13/2019

IVI to Accelerate Efforts in iNTS Vaccine Development

An award from the Wellcome Trust’s Affordable Innovations for Global Health Flagship will support IVI’s development and selection of potential vaccine candidates There is currently no vaccine available to protect against invasive non-typhoidal salmonella (iNTS)   November 13, 2019 – SEOUL, South Korea – The […]